Return to content in this issue

 

Treatment of severe atopic dermatitis with upadacitinib in real clinical practice. Short-term efficacy and safety results

Pereyra-Rodriguez JJ1, Herranz P2, Figueras-Nart I3, Perez B4, Elosua M5, Munera-Campos M6, Melgosa-Ramos J7, Zaragoza V8, Silvestre JF9, Campos-Domínguez M10, Guilabert A11, Miquel J12, Alcantara-Luna S13, de la Cueva P14, Serra-Baldrich E15, Armario-Hita JC16

1Department of Dermatology, University Hospital Virgen del Rocío, Sevilla, Spain
2Department of Dermatology, University Hospital La Paz, Madrid, Spain
3Department of Dermatology, University Hospital de Bellvitge, Barcelona, Spain
4Department of Dermatology, University Hospital Ramon y Cajal, Madrid, Spain
5Department of Dermatology, University Hospital Puerta del Hierro, Madrid, Spain
6Department of Dermatology, University Hospital Germans Trias i Pujol, Badalona, Spain
7Department of Dermatology, University Hospital Doctor Peset, Valencia, Spain
8Department of Dermatology, University Hospital General de Valencia, Spain
9Department of Dermatology, University Hospital of Alicante, Alicante, Spain
10Department of Dermatology, University Hospital Gregorio Marañón, Madrid, Spain
11Department of Dermatology, General Hospital of Granollers, Barcelona, Spain
12Department of Dermatology, University Hospital Arnau de Vilanova, Valencia, Spain
13Department of Dermatology, Juan Ramón Jimenez Hospital, Huelva, Spain
14Department of Dermatology, Infanta Leonor Hospital, Madrid, Spain
15Department of Dermatology, Sant Pau Hospital, Barcelona, Spain
16Department of Dermatology, University Hospital Puerto Real, Cádiz, Spain

J Investig Allergol Clin Immunol 2023; Vol. 33(3)
doi: 10.18176/jiaci.0831

Key words: Atopic dermatitis, Atopic eczema, Upadacitinib, JAK-inhibitors, Real world evidence